BioCryst shares fell 3.9% after earnings, with the likely concern that the quarter’s revenue included an upper-teens-of-millions contribution from CareMed’s one-time inventory build, making reported growth less representative of underlying demand. The company said ORLADEYO revenue excluding Europe still grew year over year after removing that benefit, but future revenue should more closely reflect patient demand.
BioCryst’s shares gained 3.1% following Q2 results highlighted by solid ORLADEYO revenue growth and successful pediatric launch execution, reflecting confidence in commercial momentum and operational progress.
BioCryst reported a robust Q3 2025, driven by strong revenue growth for ORLADEYO, strategic divestitures, and a clean balance sheet, setting the stage for future expansion.